Dosage of Lithiumcarbonaat PCH in details
Immediate-release capsules are usually given t.i.d. or q.i.d. Doses of controlled-release tablets are usually given b.i.d. (approximately 12-hour intervals). When initiating therapy with immediate-release or controlled-release Lithiumcarbonaat PCH, dosage must be individualized according to serum levels and clinical response.
When switching a patient from immediate-release capsules to Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR Controlled-Release Tablets, give the same total daily dose when possible. Most patients on maintenance therapy are stabilized on 900 mg daily, e.g., Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR 450 mg b.i.d. When the previous dosage of immediate-release Lithiumcarbonaat PCH is not a multiple of 450 mg, e.g., 1,500 mg, initiate Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR at the multiple of 450 mg nearest to, but below, the original daily dose, i.e., 1,350 mg. When the 2 doses are unequal, give the larger dose in the evening. In the above example, with a total daily dose of 1,350 mg, generally 450 mg of Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR should be given in the morning and 900 mg of Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR in the evening. If desired, the total daily dose of 1,350 mg can be given in 3 equal 450-mg doses of Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR. These patients should be monitored at 1- to 2-week intervals, and dosage adjusted if necessary, until stable and satisfactory serum levels and clinical state are achieved.
When patients require closer titration than that available with doses of Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR in increments of 450 mg, immediate-release capsules should be used.
Acute Mania: Optimal patient response to Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) can usually be established and maintained with 1,800 mg per day in divided doses. Such doses will normally produce the desired serum Lithiumcarbonaat PCH level ranging between 1.0 and 1.5 mEq/L.
Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient's clinical state and serum Lithiumcarbonaat PCH levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.
Long-Term Control: The desirable serum Lithiumcarbonaat PCH levels are 0.6 to 1.2 mEq/L. Dosage will vary from one individual to another, but usually 900 mg to 1,200 mg per day in divided doses will maintain this level. Serum Lithiumcarbonaat PCH levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.
Patients unusually sensitive to Lithiumcarbonaat PCH may exhibit toxic signs at serum levels below 1.0 mEq/L.
N.B.: Blood samples for serum Lithiumcarbonaat PCH determinations should be drawn immediately prior to the next dose when Lithiumcarbonaat PCH concentrations are relatively stable (i.e., 8 to 12 hours after the previous dose). Total reliance must not be placed on serum levels alone. Accurate patient evaluation requires both clinical and laboratory analysis.
Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by younger patients.
How supplied
Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) Capsules 300 mg are gray and yellow capsules imprinted with "Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) " and "SB" on one side of each half of the capsule, in bottles of 100 (NDC 0007-4007-20).
Lithiumcarbonaat PCH (Lithiumcarbonaat PCH carbonate) CR Tablets 450 mg are round, yellow, biconvex, controlled-release tablets, debossed with "SKF" and "J10" on one side and scored on the other side, in bottles of 100 (NDC 0007-4010-20).
STORAGE CONDITIONS: Store at 25°C (77°F), excursions permitted to 15-30°C (59-86°F).
Manufactured by: Cardinal Health., Winchester, KY 40391 for GlaxoSmithKline., Research Triangle Park, NC 27709. September 2003
FDA rev date: 03/11/2004
What other drugs will affect Lithiumcarbonaat PCH?
Many drugs can interact with Lithiumcarbonaat PCH. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any you start or stop using, especially:
-
carbamazepine;
-
a diuretic or "water pill";
-
fluoxetine (Prozac);
-
metronidazole;
-
potassium iodide thyroid medication;
-
heart or blood pressure medication - benazepril, candesartan, captopril, diltiazem, enalapril, lisinopril, losartan, olmesartan, telmisartan, valsartan, verapamil, and others; or
-
NSAIDs (nonsteroidal anti-inflammatory drugs) - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others.
This list is not complete and many other drugs can interact with Lithiumcarbonaat PCH. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Give a list of all your medicines to any healthcare provider who treats you.
Lithiumcarbonaat PCH interactions
Caution should be used when Lithiumcarbonaat PCH and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of Lithiumcarbonaat PCH and increase serum Lithiumcarbonaat PCH levels with risk of Lithiumcarbonaat PCH toxicity. Patients receiving such combined therapy should have serum Lithiumcarbonaat PCH levels monitored closely and the Lithiumcarbonaat PCH dosage adjusted if necessary.
Lithiumcarbonaat PCH levels should be closely monitored when patients initiate or discontinue NSAID use. In some cases, Lithiumcarbonaat PCH toxicity has resulted from interactions between an NSAID and Lithiumcarbonaat PCH. Indomethacin and piroxicam have been reported to increase significantly steady-state plasma Lithiumcarbonaat PCH concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state Lithiumcarbonaat PCH plasma levels increased approximately 17% in subjects receiving Lithiumcarbonaat PCH 450 mg b.i.d. with celecoxib 200 mg b.i.d. as compared to subjects receiving Lithiumcarbonaat PCH alone.
Concurrent use of metronidazole with Lithiumcarbonaat PCH may provoke Lithiumcarbonaat PCH toxicity due to reduced renal clearance. Patients receiving such combined therapy should be monitored closely.
There is evidence that angiotensin-converting enzyme inhibitors, such as enalapril and captopril, and angiotension II receptor antagonists, such as losartan, may substantially increase steady-state plasma Lithiumcarbonaat PCH levels, sometimes resulting in Lithiumcarbonaat PCH toxicity. When such combinations are used, Lithiumcarbonaat PCH dosage may need to be decreased, and plasma Lithiumcarbonaat PCH levels should be measured more often.
Concurrent use of calcium channel blocking agents with Lithiumcarbonaat PCH may increase the risk of neurotoxicity in the form of ataxia, tremors, nausea, vomiting, diarrhea, and/or tinnitus. Caution is recommended.
The concomitant administration of Lithiumcarbonaat PCH with selective serotonin reuptake inhibitors should be undertaken with caution as this combination has been reported to result in symptoms such as diarrhea, confusion, tremor, dizziness, and agitation.
The following drugs can lower serum Lithiumcarbonaat PCH concentrations by increasing urinary Lithiumcarbonaat PCH excretion: acetazolamide, urea, xanthine preparations, and alkalinizing agents such as sodium bicarbonate.
The following have also been shown to interact with Lithiumcarbonaat PCH: methyldopa, phenytoin, and carbamazepine.
Reviews
The results of a survey conducted on ndrugs.com for Lithiumcarbonaat PCH are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lithiumcarbonaat PCH. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
